The main risk factors for cardiovascular disease are diabetes, hypertension and obesity. It can be assumed that the importance of this disease will be even higher going forward.
But investments in cardiovascular drug development are much lower than in other therapeutic areas. One explanation is the high cost of conducting large cardiovascular trials. The need for successful prevention strategies, access to existing therapies and the development of new innovative drugs offer attractive investment opportunities.